anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
AstraZeneca · conference-presentation

AstraZeneca | Investor Day Presentation Deck | 49 slides

49 pages · 5 arc beats · 3 loops

Conference-Presentation Download JSON
Unlock

AstraZeneca | Investor Day Presentation Deck | 49 slides

AstraZeneca · 2022-09
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 49 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Situation & Context 4 slides 100% 4/4 slides 100% 4/4 slides · 17 hits
— 0/4 slides
25% 1/4 slides
— 0/4 slides
100% 4/4 slides
— 0/4 slides
Problem & Complication 5 slides 100% 5/5 slides 100% 5/5 slides · 28 hits
— 0/5 slides
40% 2/5 slides 20% 1/5 slides 100% 5/5 slides 100% 5/5 slides Solution & Approach 10 slides 100% 10/10 slides 100% 10/10 slides · 66 hits
— 0/10 slides
30% 3/10 slides · 4 hits 40% 4/10 slides 100% 10/10 slides 100% 10/10 slides Evidence & Proof 10 slides 100% 10/10 slides 100% 10/10 slides · 63 hits
— 0/10 slides
40% 4/10 slides · 5 hits 30% 3/10 slides 100% 10/10 slides 100% 10/10 slides Impact & Next Steps 20 slides 100% 20/20 slides 100% 20/20 slides · 108 hits
— 0/20 slides
45% 9/20 slides 30% 6/20 slides 100% 20/20 slides
— 0/20 slides

Slide inventory

49
every slide · same image gating as the playbook
01
Slide 1
Features a photo of a child named Albie living with LAL-D.front_matter
Open slide detailBeat · Situation & Context
02
other
Open slide detailBeat · Situation & Context
03
front_matter
Open slide detailBeat · Situation & Context
04
transition
Open slide detailBeat · Situation & Context
05
present_solution
Open slide detailBeat · Problem & ComplicationLoop · Golden Circle
06
The slide uses iconography to represent key statistics about rare diseases.establish_context
Open slide detailBeat · Problem & ComplicationLoop · Golden Circle
07
summarize
Open slide detailBeat · Problem & ComplicationLoop · Golden Circle
08
The slide uses a visual mapping of products to indications.establish_context
Open slide detailBeat · Problem & ComplicationLoop · Golden Circle
09
The slide uses a horizontal bar chart format to represent clinical trial progress.plan_implementation
Open slide detailBeat · Problem & ComplicationLoop · Golden Circle
10
The slide uses a human-centric image to transition into a business section about medical leadership.transition
Open slide detailBeat · Solution & ApproachLoop · Mece Breakdown
11
The slide uses a matrix-like layout to map drug candidates against biological targets and development status.present_solution
Open slide detailBeat · Solution & ApproachLoop · Mece Breakdown
12
The slide uses a biological process flow to explain the therapeutic rationale for C5 inhibition.present_framework
Open slide detailBeat · Solution & ApproachLoop · Mece Breakdown
13
The slide uses a timeline-like arrow to represent innovation and expansion into new indications.present_solution
Open slide detailBeat · Solution & ApproachLoop · Mece Breakdown
14
The slide uses a waterfall-style comparison for pricing and a 2x2 grid for indication-specific growth strategies.summarize
Open slide detailBeat · Solution & ApproachLoop · Mece Breakdown
15
Includes clinical trial data (Study 301) and registry survival analysis.analyze_data
Open slide detailBeat · Solution & ApproachLoop · Mece Breakdown
16
HLR = high-level results; gMG = generalised myasthenia gravis; MG-ADL = myasthenia gravis activities of daily living; QMG = quantitative myasthenia gravis.summarize
Open slide detailBeat · Solution & ApproachLoop · Mece Breakdown
17
Includes three distinct data visualizations: a bar chart for median MG-ADL, a box plot for change from baseline, and a line chart for mean MG-ADL over time.analyze_data
Open slide detailBeat · Solution & ApproachLoop · Mece Breakdown
18
Includes 'Number at risk' table below the x-axis.analyze_data
Open slide detailBeat · Solution & ApproachLoop · Mece Breakdown
19
The slide uses a Kaplan-Meier survival curve for HSCT-TMA and market sizing metrics for CSA-AKI.quantify_opportunity
Open slide detailBeat · Solution & ApproachLoop · Mece Breakdown
20
The slide uses a combination of a timeline/map graphic and a bar chart to demonstrate market penetration and adoption speed.analyze_data
Open slide detailBeat · Evidence & ProofLoop · Quick Win Big Bet
21
Comparison of molecular weight (25 kDa vs 150 kDa) and administration method.present_solution
Open slide detailBeat · Evidence & ProofLoop · Quick Win Big Bet
22
Includes clinical trial design diagram for Part A and Part B.diagnose_problem
Open slide detailBeat · Evidence & ProofLoop · Quick Win Big Bet
23
Includes a biological pathway diagram and a comparison of circulating concentrations.present_solution
Open slide detailBeat · Evidence & ProofLoop · Quick Win Big Bet
24
The slide uses a horizontal timeline-like structure to compare three drug candidates (ALXN2040, ALXN2050, ALXN2080).plan_implementation
Open slide detailBeat · Evidence & ProofLoop · Quick Win Big Bet
25
Includes FDA Breakthrough Designation callout and trial design diagrams.summarize
Open slide detailBeat · Evidence & ProofLoop · Quick Win Big Bet
26
The slide uses a human-centric approach to introduce a strategic section.transition
Open slide detailBeat · Evidence & ProofLoop · Quick Win Big Bet
27
The slide uses a pyramid to segment the market by patient need and product modality.present_solution
Open slide detailBeat · Evidence & ProofLoop · Quick Win Big Bet
28
Uses a pictograph to represent patient population segments.present_solution
Open slide detailBeat · Evidence & ProofLoop · Quick Win Big Bet
29
The chart shows a comparison of branded vs unbranded/off-label market size over time, and a pie chart showing patient source.quantify_opportunity
Open slide detailBeat · Evidence & ProofLoop · Quick Win Big Bet
30
The slide uses a combination of scientific evidence (left) and market/trial status (right) to justify investment.size_opportunity
Open slide detailBeat · Impact & Next Steps
31
The slide uses a matrix layout to map drug assets against biological targets and development status (marketed, late-stage, early-stage, preclinical).present_framework
Open slide detailBeat · Impact & Next Steps
32
The slide uses a high-emotion photo of a father and son to humanize the medical topic.transition
Open slide detailBeat · Impact & Next Steps
33
The slide uses a matrix-like layout to map drug assets against therapeutic areas and development status.plan_implementation
Open slide detailBeat · Impact & Next Steps
34
Includes a visual representation of the metabolic pathway and radiographic evidence of treatment efficacy.diagnose_problem
Open slide detailBeat · Impact & Next Steps
35
The slide uses a Venn-style diagram to illustrate market expansion.size_opportunity
Open slide detailBeat · Impact & Next Steps
36
The slide uses a process diagram to illustrate the pathophysiology of two distinct types of amyloidosis.diagnose_problem
Open slide detailBeat · Impact & Next Steps
37
The slide uses a comparative structure to map assets to specific disease indications and their clinical progress.plan_implementation
Open slide detailBeat · Impact & Next Steps
38
The slide uses a process flow for the trial design and a table for disease staging and median overall survival (OS).present_solution
Open slide detailBeat · Impact & Next Steps
39
The slide uses a matrix-like layout to categorize drugs by disease area and development stage (marketed, late-stage, early-stage).summarize
Open slide detailBeat · Impact & Next Steps
40
The slide uses a circular overlay on a stock photo of a business meeting.transition
Open slide detailBeat · Impact & Next Steps
41
The slide uses a timeline-based map visualization to illustrate market penetration goals.size_opportunity
Open slide detailBeat · Impact & Next Steps
42
The slide uses a map to anchor the geographic focus and a table to list specific drug approvals by disease category.size_opportunity
Open slide detailBeat · Impact & Next Steps
43
transition
Open slide detailBeat · Impact & Next Steps
44
The slide uses a bridge metaphor to represent the collaboration between the two entities.present_solution
Open slide detailBeat · Impact & Next Steps
45
present_solution
Open slide detailBeat · Impact & Next Steps
46
summarize
Open slide detailBeat · Impact & Next Steps
47
summarize
Open slide detailBeat · Impact & Next Steps
48
other
Open slide detailBeat · Impact & Next Steps
49
other
Open slide detailBeat · Impact & Next Steps